Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
iBio, Inc. issued pre-funded warrants to purchase up to 9,653,257 shares of common stock of warrant to institutional investors for purchase price per pre-funded warrant of $2.349 (equal to share price minus $0.001 exercise price).
- Security
- warrant
- Shares
- pre-funded warrants to purchase up to 9,653,257 shares of common stock
- Purchaser
- institutional investors
- Consideration
- purchase price per pre-funded warrant of $2.349 (equal to share price minus $0.001 exercise price)
Exact text from the filing
On January 8, 2026, iBio, Inc., a Delaware company (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC (the “Private Placement”) an aggregate of 1,408,481 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 9,653,257 shares of Common Stock (the “Pre-Funded Warrant Shares”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.98
iBio, Inc. issued 1,408,481 shares of common stock of common stock to institutional investors for purchase price per share of $2.35; aggregate gross proceeds approx. $26 million.
- Security
- common stock
- Shares
- 1,408,481 shares of common stock
- Purchaser
- institutional investors
- Consideration
- purchase price per share of $2.35; aggregate gross proceeds approx. $26 million
Exact text from the filing
warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 9,653,257 shares of Common Stock (the “Pre-Funded Warrant Shares”). The purchase price per Share is $2.35. The purchase price per Pre-Funded Warrant is $2.349, which is equal to the purchase price per Share, minus the exercise price of $0.001 for each Pre-Funded Warrant. The Private
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
iBio, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $26 million (effective 2026-01-08).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors
- Value
- approximately $26 million
- Effective
- 2026-01-08
Exact text from the filing
On January 8, 2026, iBio, Inc., a Delaware company (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a private placement priced at-the-market consistent with the rules of the Nasdaq Stock Market LLC (the “Private Placement”) an aggregate of 1,408,481 shares (the “Shares”) of the Company’s common stock
View on SEC.gov